Updates of adjuvant therapy in pancreatic cancer: Where are we and where are we going?

Journal of the Pancreas

Volumn 11, Issue 4, 2010, Pages 310-312

  Li, Jia ^a   Merl, Man Yee ^b   Chabot, John ^c   Saif, Muhammad Wasif ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE NEW HAVEN HOSPITAL   (United States)

^c Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Adjuvant; Chemotherapy; Gemcitabine; Immunotherapy; Pancreatic neoplasms

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CA 19-9 ANTIGEN; CAPECITABINE; CETUXIMAB; CISPLATIN; CYTOTOXIC AGENT; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; GI 400; GI 4000; PLACEBO; UNCLASSIFIED DRUG; IMMUNOLOGICAL ADJUVANT;

BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; ERYTHEMA; HUMAN; INJECTION SITE INDURATION; MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PANCREAS CANCER; PANCREAS SURGERY; REVIEW; SURVIVAL TIME; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; CARCINOMA; EVALUATION STUDY; IMMUNOTHERAPY; MEDICAL SOCIETY; MULTIMODALITY CANCER THERAPY; ONCOLOGY; ORGANIZATION; PANCREATIC NEOPLASMS; PROCEDURES; TRENDS; UNITED STATES;

ADJUVANTS, IMMUNOLOGIC; CARCINOMA; CHEMOTHERAPY, ADJUVANT; CHICAGO; COMBINED MODALITY THERAPY; CONGRESSES AS TOPIC; HUMANS; IMMUNOTHERAPY; MEDICAL ONCOLOGY; PANCREATIC NEOPLASMS; RADIOTHERAPY, ADJUVANT; SOCIETIES, MEDICAL; UNITED STATES;

EID: 77954794411     PISSN: None     EISSN: 15908577     Source Type: Journal    
DOI: None     Document Type: Review

References (10)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer Statistics, 2009. CA Cancer J Clin 2009; 59:225-49. [PMID 19474385]
2. Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 2007; 297:267-77. [PMID 17227978]
3. Hardacre JM, Mulcahy MF, Talamonti M, Obel JC, Rocha Lima S, Safran H, et al. Effect of hyperacute immunotherapy in addition to standard adjuvant therapy for resected pancreatic cancer on disease-free and overall survival: Preliminary analysis of phase II data. J Clin Oncol 2010; 28(15 Suppl):4059.
4. Marten A, Schmidt J, Debus J, Harig S, Lindel K, Klein J, et al. CapRI: Final results of the open-label, multicenter, randomized phase III trial of adjuvant chemoradiation plus interferon-?2b (CRI) versus 5-FU alone for patients with resected pancreatic adenocarcinoma (PAC). J Clin Oncol 2010; 28(18 Suppl):LBA4012.
5. Picozzi VJ, Abrams RA, Traverso LW, O'Reilly EM, Greeno E, Martin RC, et al. ACOSOG Z05031: Report on a multicenter, phase II trial for adjuvant therapy of resected pancreatic cancer using cisplatin, 5- FU, and alpha-interferon. J Clin Oncol 2008; 26(15 Suppl):4505.
6. Whiting SH, Muscarella P, Rosemurgy A, Fisher WE, Richards DA, Harrell FE Jr, et al. A randomized, placebo-controlled, multicenter phase II adjuvant trial of the efficacy, immunogenicity, and safety of GI-4000 plus gemcitabine versus gemcitabine alone in patients with resected pancreatic cancer with activating ras mutations. J Clin Oncol 2010; 28(15 Suppl):TPS226.
7. Berlin J, Catalano PJ, Feng Y, Lowy AM, Blackstock AW, Philip PA, et al. ECOG 2204: An intergroup randomized phase II study of cetuximab (Ce) or bevacizumab (B) in combination with gemcitabine (G) and in combination with capecitabine (Ca) and radiation (XRT) as adjuvant herapy (Adj Tx) for patients (pts) with completely resected pancreatic adenocarcinoma (PC). J Clin Oncol 2010; 28(15 Suppl):4034.
8. Ishii H, Ueno H, Kosuge T, Matsuyama Y, Saiura A, Nakao A, et al. A phase I/II trial of gemcitabine and S-1 therapy in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer (JSAP-03). J Clin Oncol 2010; 28(Suppl):e14625.
9. Vaccaro V, Fleming JB, Wolff RA, Evans DB, Tamm EP, Crane CH, et al. Role of surveillance CT scans in resected PC: Correlation with CA19-9 and symptoms. J Clin Oncol 2010; 28(15 Suppl):4113.
10. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™). Pancreatic Adenocarcinoma. V.I.2010. Fort Washington, PA, USA.